Results 141 to 150 of about 182,500 (270)

Real‐World Experience With Multimodal Treatment of Resectable Stage II–III Non‐Small Cell Lung Cancer: A Single Institutional Analysis

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Neoadjuvant therapy has recently become an integral component of multimodal treatment for resectable lung cancer. However, real‐world data on perioperative morbidity and treatment adherence remain limited. This study aimed to assess the feasibility and safety of different neoadjuvant treatment approaches applied within daily clinical routine ...
Raffaella Griffo   +14 more
wiley   +1 more source

The Use of Combination Palliative Radiotherapy and Single‐Agent Immunotherapy for the Management of Head and Neck Squamous Cell Carcinoma (HNSCC) in the United Kingdom (UK)

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Clinical data on combined Immunotherapy (IO) and palliative radiotherapy (RT) in HNSCC is scarce. HNSCC Palliative RT differs from curative intent RT as it does not involve elective nodal irradiation; therefore, an immune response may be more likely.
Chris Hurt   +21 more
wiley   +1 more source

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

open access: yesiNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu   +5 more
wiley   +1 more source

Immune‐Related Prognostic Gene Identification in Lung Squamous Cell Carcinoma With the Cancer Genome Atlas Mining and Immunohistochemistry Validation

open access: yesiNew Medicine, EarlyView.
ABSTRACT Objective In the cancer microenvironment, stromal and immune cells hold clinical importance. In lung squamous cell carcinoma (LSCC), the aim of this study was to find immune‐linked gene expression that has prognostic pertinence. Methods From the Cancer Genome Atlas, this study obtained the LSCC gene expression profile.
Weijia Jiang   +5 more
wiley   +1 more source

When Explant Surprises: Management and Outcomes of Hepatocellular Carcinoma Beyond Milan Criteria Discovered Post‐Transplant‐ A Narrative Review of Literature

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan.
Serkan Sucu   +2 more
wiley   +1 more source

Pelvic Exenteration for Cervical Cancer: Oncological, Morbidity and Quality of Life Outcomes

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives One third of patients who undergo definitive chemoradiotherapy for locally advanced cervical cancer develop disease recurrence. Salvage surgery in the form of pelvic exenteration (PE) may offer improved survival and possibly cure in carefully selected patients, however robust data is scarce.
Alexandra M. Peacock   +6 more
wiley   +1 more source

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto   +7 more
wiley   +1 more source

Long‐Term Clinical Response After Low‐Dose and Short‐Duration Cemiplimab Therapy in a Patient With Xeroderma Pigmentosum in Nepal

open access: yesJEADV Clinical Practice, EarlyView.
Capsule Summary Xeroderma pigmentosum (XP) is associated with a high risk of multiple and aggressive cutaneous squamous cell carcinomas (CSCCs). The immune checkpoint inhibitor cemiplimab has been approved in advanced, unresectable, and/or metastatic CSCCs.
Sudip Parajuli   +5 more
wiley   +1 more source

Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes.
Miguel A. Aristizabal‐Torres   +4 more
wiley   +1 more source

Pembrolizumab-Induced Isolated Adrenocorticotropic Hormone (ACTH) Deficiency

open access: yes
Pembrolizumab is a programmed death 1 receptor (PD-1) inhibitor. It is used as immunotherapy in various cancers, including metastatic melanoma, non-small cell lung cancer, and, notably, high-risk triple-negative breast cancer.
Han, Hye Jeong, Alfares, Khalid
core  

Home - About - Disclaimer - Privacy